A068270 Stock Overview
Develops and produces drugs based on proteins for the treatment of oncology in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for A068270 from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Celltrion, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩158,700.00 |
| 52 Week High | ₩200,952.38 |
| 52 Week Low | ₩150,400.00 |
| Beta | 0.58 |
| 1 Month Change | -3.23% |
| 3 Month Change | -13.75% |
| 1 Year Change | -6.02% |
| 3 Year Change | 10.03% |
| 5 Year Change | -27.00% |
| Change since IPO | 1,576.81% |
Recent News & Updates
Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt
May 03
Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear
Apr 09Recent updates
Celltrion (KRX:068270) Takes On Some Risk With Its Use Of Debt
May 03Celltrion, Inc.'s (KRX:068270) Popularity With Investors Is Clear
Apr 09Estimating The Intrinsic Value Of Celltrion, Inc. (KRX:068270)
Jan 06Is Celltrion (KRX:068270) A Risky Investment?
Dec 10Celltrion's (KRX:068270) Weak Earnings May Only Reveal A Part Of The Whole Picture
Nov 22Here's Why Celltrion (KRX:068270) Has A Meaningful Debt Burden
Jun 26Shareholder Returns
| A068270 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | 3.4% | 1.5% | 1.5% |
| 1Y | -6.0% | 20.2% | -3.0% |
Return vs Industry: A068270 underperformed the KR Biotechs industry which returned 20.2% over the past year.
Return vs Market: A068270 underperformed the KR Market which returned -3% over the past year.
Price Volatility
| A068270 volatility | |
|---|---|
| A068270 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 8.4% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in KR Market | 12.5% |
| 10% least volatile stocks in KR Market | 3.0% |
Stable Share Price: A068270 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A068270's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 2,391 | Hyong-Gi Kim | www.celltrion.com |
Celltrion, Inc., together with its subsidiaries, develops and produces drugs based on proteins for the treatment of oncology in South Korea. The company markets biopharmaceuticals; generic pharmaceuticals; and covid-19 test kits. Its antibody biosimilar pipeline includes CT-P44 that is in phase 3 clinical trial for the treatment of multiple myeloma; CT-P51, which is in phase 3 clinical trial for the treatment of Melanoma, lung cancer; CT-P53, which is in phase 3 clinical trial for the treatment of multiple sclerosis; and CT-P55 that is in phase 3 clinical trial for the treatment of Psoriasis.
Celltrion, Inc. Fundamentals Summary
| A068270 fundamental statistics | |
|---|---|
| Market cap | ₩33.84t |
| Earnings (TTM) | ₩508.92b |
| Revenue (TTM) | ₩3.66t |
Is A068270 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A068270 income statement (TTM) | |
|---|---|
| Revenue | ₩3.66t |
| Cost of Revenue | ₩1.84t |
| Gross Profit | ₩1.82t |
| Other Expenses | ₩1.31t |
| Earnings | ₩508.92b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.39k |
| Gross Margin | 49.64% |
| Net Profit Margin | 13.90% |
| Debt/Equity Ratio | 12.7% |
How did A068270 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/29 19:46 |
| End of Day Share Price | 2025/05/29 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Celltrion, Inc. is covered by 41 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Girish Bakhru | BofA Global Research |
| Dae Woong Yoo | Bookook Securities Co. Ltd |
| Aaron Ho | CFRA Equity Research |